MedTrace Logo

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension

NCT01054105 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 73

Last updated 2018-12-27

No results posted yet for this study

Summary

In the present study, the investigators want to investigate the prevalence of BMPR-2 gene mutations in the Korean PAH patients (Step-I) and to test that the PAH patients treated with iloprost inhalation solution (Ventavis®) would show hemodynamic response, especially assessed by exercise echocardiography (Step-II).

Conditions

Interventions

DRUG

Iloprost

Iloprost inhalation, 2.5 - 5mcg, 6 times per day

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Seoul National University Bundang Hospital

    collaborator OTHER

  • The Catholic University of Korea

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Gachon University Gil Medical Center

    lead OTHER

Principal Investigators

  • Wook-Jin Chung, MD,PhD · Gachon University Gil Medical Center

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2018-12-25
Completion
2018-12-25

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01054105 on ClinicalTrials.gov